MetaCap

Attovia Therapeutics Inc. (ATTO)

NASDAQ: ATTOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

15.10-0.48 (-3.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ATTO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$690.26M
EPS (TTM)
-$5.53
52-week range
12.94 – 28.00
Day range
14.80 – 15.46
Volume / Avg
372.22K / 337.27K
Beta
—
Next earnings
Dec 2, 2026

52-week range

$12.94$28.00

ATTO stock today

Shares of Attovia Therapeutics (ATTO) finished lower on Nov 20 at $15.10, a drop of 3.08% or $0.48 per share, versus the S&P 500's 3.70% decline. At this level, ATTO sits near the bottom of its 52-week range of $12.94 to $28.00: 46.1% below the high, set on Sep 8, 2026 and 16.7% above the low. Attovia Therapeutics has posted a net loss over the last twelve months (EPS of -$5.53), so its P/E ratio is not meaningful.

The company is scheduled to report Sep/2026 results on Dec 2; analysts expect EPS of -$0.74.

Summary generated from market data by MetaCap's automated system. Methodology

About Attovia Therapeutics

Company profile

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD).

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Tao Fu M.B.A., M.S.
Headquarters
San Carlos, CA
Employees
50
IPO year
2026

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$43.20+186.09%

  • Strong buy 2
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $34.00High $52.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 2, 2026
EPS estimate
$-0.74
Last reported (Sep/2026)
Dec 2, 2026
EPS actual vs est.
$-0.76 vs $-0.74
Surprise
-2.70%

ATTO news

All ATTO news

Attovia Therapeutics peers

Health Care sector
ATTO peer companies
CompanyPrice% ChgMarket capCompare
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs ATTO
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs ATTO
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs ATTO
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs ATTO
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs ATTO
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs ATTO
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs ATTO
CGEMCullinan Therapeutics Inc.8.89-1.98%$577.15Mvs ATTO

Indexes, lists and sector

Attovia Therapeutics stock FAQ

What is Attovia Therapeutics's stock price today?

ATTO last traded at $15.10 as of Nov 20, 4:00 PM EST, down 3.08% on the day. Prices are delayed at least 15 minutes.

When is Attovia Therapeutics's next earnings date?

Attovia Therapeutics is expected to report earnings on Wednesday, December 2, 2026. Analysts expect EPS of $-0.74.

Who is Attovia Therapeutics's CEO?

Mr. Tao Fu M.B.A., M.S. is the chief executive officer of Attovia Therapeutics Inc., which has about 50 employees.

What is the ATTO 52-week high?

The 52-week high for ATTO is $28.00 and the 52-week low is $12.94. The stock is currently 46.1% below its high.

Compare ATTO